Fresenius Medical Care AG & Co. KGaA

As of June 30, 2026, Fresenius Medical Care AG & Co. KGaA has 270.09M shares outstanding.

As of June 30, 2026, Fresenius Medical Care AG & Co. KGaA trades at a trailing price-to-earnings ratio of 15.75.

As of June 30, 2026, Fresenius Medical Care AG & Co. KGaA trades at an EV/EBITDA multiple of 4.17 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 0.75 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 7.65 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Fresenius Medical Care AG & Co. KGaA trades at an EV/FCF ratio of 3.63, comparing the total takeover cost of the business to the cash it actually generates for all capital providers.

As of June 30, 2026, Fresenius Medical Care AG & Co. KGaA maintains a current ratio of 4.90, meaning it holds 4.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 309.55, indicating elevated leverage, while an interest coverage ratio of 9.18 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Fresenius Medical Care AG & Co. KGaA posted a return on equity (ROE) of 10.84, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 8.94 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.60, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 6.10, useful for judging operating efficiency across full business cycles. Inventory turnover of 10.78 indicates how many times Fresenius Medical Care AG & Co. KGaA sells and replaces its inventory over a year, a key working capital efficiency ratio.

These figures cover the twelve months ended June 30, 2026. That works out to an effective tax rate of 20.06, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

Over the twelve months ended June 30, 2026, Fresenius Medical Care AG & Co. KGaA posted a gross margin of 26.16, reflecting its pricing power and cost economics. The operating margin of 9.79 and net profit margin of 4.94 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 24.49, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 16.30, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Fresenius Medical Care AG & Co. KGaA shareholders.

As of June 30, 2026, Fresenius Medical Care AG & Co. KGaA has an Altman Z-Score of 11.29, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.